Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Few drugs are approved in the United States to treat dry eye disease (DED). AbbVie’s blockbuster Restasis was the only therapy approved for this indication for more than a decade until the launch…
MARKET OUTLOOK Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality,…
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous…
MARKET OUTLOOK Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs)…
Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two…
The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year…
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…
Postoperative pain is one of the key segments comprising the larger market for acute pain therapies. It has experienced strong growth over the past decade owing to the uptake of Pacira BioSciences…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…
For the 3.8 million people in the United States with Alzheimer’s disease (AD) dementia, approved pharmacotherapy is limited to only modestly effective procognitive symptomatic agents (e.g.,…